NCT05395507View on ClinicalTrials.gov

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
Essential Thrombocytopenia
Interventions
DRUG

Recombinant Interferon Alpha

Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.

DRUG

Pegylated interferon alfa-2b

Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER